Researchers have developed a handheld multi-material bioprinter with applications ranging from wound repair to custom prosthetics. The bioprinter, details of which were published in the journal Biofabrication, improves on earlier devices by enabling the printing of multiple materials and giving control over the properties of printed tissues. Printing multiple materials could improve tissue biomimicry and facilitate the simultaneous or sequential dispensing of different materials and cells. Researchers at the University of Victoria and University of Montreal used the device to print multiple cells, drug-releasing meshes and sensors.
Bioprinting technology has advanced over the past decade. In 2016, researchers shared details of a handheld device for surgical printing of adipose stem cells, and in 2020 another team loaded a device with pore-forming bio-ink for in situ wound dressing.
The latest study addresses some of the limitations of those older technologies. A temperature control module supports long-term printing, and print heads that allow the flow of several bio-inks enable multi-material printing, resulting in a device capable of depositing hydrogel fibers and different types of cells such as dermal fibroblasts.
Using the device, the researchers printed directly on artificially created pig skin wounds. Mohsen Akbari, one of the authors of the paper and an associate professor at the University of Victoria in Canada, explained some of the applications in an article from the Institute of Physics’ IOP Publishing. READ MORE
By Nick Paul Taylor
Source: medtechdive.com
Researchers at the University of Copenhagen, Denmark, have used a wireless motility capsule to reveal how changes in the gut environment impact bacteria composition and activity. The team believes the findings may help explain differences in people’s gut microbial composition and metabolism.
The approval enables the treatment of adults with moderate to severe CHE when topical corticosteroids are inadequate or inappropriate. The decision was based on the positive outcomes of the Phase III programme, which encompassed the DELTA 1 and DELTA 2 trials. The trials assessed the cream’s efficacy and safety against a cream vehicle, meeting their primary and secondary goals.
With the new plant, to be located in the Beijing Economic and Technological Development Zone, the Paris-based French drugmaker wants to significantly expand its production capacity in Asia, the company explained via the Chinese messaging service WeChat.
